OncoMatch/Clinical Trials/NCT05870475
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Is NCT05870475 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Pegylated interferon α-2b for polycythemia vera.
Treatment: Ruxolitinib · Pegylated interferon α-2b — Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Prior therapy
Must have received: hydroxyurea (hydroxyurea)
Resistant or intolerant to hydroxyurea (based on the 2013 European LeukemiaNet criteria).
Cannot have received: interferon
Exception: washout period >= 4 weeks
Have not previously received interferon preparations or ruxolitinib treatment, or the washout period between the last use of interferon preparations or ruxolitinib and the first use of the study drug should not be less than 4 weeks.
Cannot have received: ruxolitinib (ruxolitinib)
Exception: washout period >= 4 weeks
Have not previously received interferon preparations or ruxolitinib treatment, or the washout period between the last use of interferon preparations or ruxolitinib and the first use of the study drug should not be less than 4 weeks.
Cannot have received: investigational drug
Use of any investigational drug or participation in any other clinical trial within 4 weeks prior to the first dose of the study drug, or failure to recover from any effects of previously administered study drugs
Lab requirements
Blood counts
female hemoglobin (hgb) ≥10g/dl, male hemoglobin (hgb) ≥11g/dl; neutrophil count ≥1.5×109/l; platelet count ≥100×109/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify